Clinical Trial TitleThe Essence Study: Investigating the effect of semaglutide in subjects with non-cirrhotic non-alcoholic steatohepatitis
Clinical Trial Protocol Description:
The Essence Study is investigating the effect of semaglutide compared to placebo in subjects with non-alcoholic steatohepatitis (NASH) and Stage 3 fibrosis. This is an injectable drug administered every week.
Clinical Trial Eligibility Criteria:
In order to participate you must meet the following criteria:
- Have histological evidence of fibrosis stage 3 based on a liver biopsy
- Have a histological NAS score greater than or equal to 4
- Not have documented causes of chronic liver disease other than non-alcoholic fatty liver disease
- Not have a HbA1c greater than 9.5% at screening.
This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.